AWM
IPSC icon

Avior Wealth Management’s Century Therapeutics IPSC Stock Holding History

Avior Wealth Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$25 – 2985
2024
Q1 		$25 Buy
+6
New +$25 ﹤0.01% 3650

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Avior Wealth Management's IPSC Position: Q2 2024 in Review

Avior Wealth Management sold out of Century Therapeutics (IPSC) in Q2 2024, closing a stake of 6 shares — an estimated $25 sold.

Avior Wealth Management first reported a position in IPSC in Q1 2024 and held it in 1 quarter. The position peaked at $25 in Q1 2024. 61 funds tracked by Wall St. Rank hold IPSC as of Q2 2024.

  • Avior Wealth Management reported no remaining Century Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 6 Century Therapeutics shares in Q2 2024, an estimated $25.
  • Avior Wealth Management first reported a position in Century Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Century Therapeutics position peaked at $25 in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.